GSK tangoes with private equity players to explore $54B sale of consumer unit instead of IPO — report
The spinout of GlaxoSmithKline’s consumer health unit could reportedly take the form of a $54 billion sale to private equity firms.
It would mark a pivot from previous plans to turn that group into its own listed company — one in which current GSK shareholders can continue to own a stake — amid intense pressure from a pair of activist investors calling for a drastic shakeup at the top.
Advent International, CVC Capital Partners, KKR & Co and Permira are among potential suitors currently vetting the business, Bloomberg reported Tuesday, as are Blackstone and Carlyle Group, which have been heavily involved in life sciences deals in recent years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.